Rare neuromuscular & neurological diseases: why a different CRO model is needed

Clinical trials in rare neuromuscular and neurological diseases demand more than traditional execution.  They require a fundamentally different approach. In these studies, many of the most significant challenges are operational: caregiver burden can limit participation, patient fatigue can affect retention and compliance, and site burden can slow enrollment and strain execution.

Success depends on more than clinical expertise alone. It requires adaptability, a deep understanding of the patient and caregiver journey, and a model designed to address these real-world challenges.

This is where Stiris Research takes a different approach.  As a full-service CRO with over two decades of experience, we have built a high-engagement model that brings sites, patients, and caregivers into close alignment, reducing burden, strengthening participation, and enabling successful delivery of complex neuromuscular and neurological trials.

The challenge of clinical trials in rare neuromuscular and neurological diseases

Rare neuromuscular and neurological diseases, including Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS), present a unique set of challenges. Patient populations are small and often geographically dispersed, disease progression can vary significantly between individuals, and assessment criteria must capture a combination of function, mobility, and quality of life. These complexities are further compounded by the significant burden placed on patients and their caregivers, as well as the need for long-term studies.

At the same time, the clinical research landscape is evolving: sponsors in biopharma and biotechnology are moving toward combination therapies, earlier interventions, long-term extension studies, and more nuanced functional endpoints. This all increases operational complexity, particularly in pediatric and adult clinical trials in the neuromuscular and neurological space, where pediatric trials require close coordination with families and caregivers.​

In this context, traditional clinical research models are not enough. Precision, flexibility, and empathy are needed at every stage of the study in order for clinical trials in rare neuromuscular diseases to be feasible and to generate high‑quality data.​

Stiris Research: a CRO specialized in rare diseases and neuromuscular/neurological trials

For over two decades, Stiris Research has worked hand‑in‑hand with sponsors and investigators to advance research in rare diseases, including in the neuromuscular and neurological field. Our approach combines operational expertise, patient‑centered trials, high‑quality clinical trial management, and flexible solutions tailored to the realities of each study and designed around the complexity of these trials.

We are a CRO for biotech and pharma companies seeking a specialized partner for clinical trial management in Phase I–IIIB studies in rare neuromuscular and neurological diseases and other complex disorders.

1. Designed for the complexity of neuromuscular and neurological trials

With a strong track record across Phase I, II, III, and IIIb, Stiris understands the unique complexities of neuromuscular and neurological studies, including their long duration, variable disease progression, demanding clinical endpoints and significant site burden, as well as the emotional and physical demands placed on patients and caregivers.

We don’t offer a one‑size‑fits‑all approach. Instead, we provide a service specifically built for this landscape, with no improvised adaptations, and with a true end‑to‑end clinical development mindset in rare diseases.

2. Clinically experienced teams

One hundred percent of Stiris’ team has experience in rare diseases, and around 60% hold nursing degrees, reinforcing our clinical and patient‑centric orientation. This deep clinical knowledge enables more informed decision‑making, a better understanding of patient progression, and the ability to anticipate operational challenges at each research center.

3. Patient‑ and caregiver‑centered focus

In every study, patients and caregivers sit at the heart of decision‑making. Stiris leverages its Patient & Caregiver Liaison (PCL) service to provide continuous support, reducing the burden associated with visits, travel, and coordination. This ongoing engagement not only enhances the experience for patients and caregivers but also plays a critical role in supporting their retention throughout demanding, long-running trials, ultimately improving the quality of data collected in patient‑centered trials.​

Our solutions are specifically designed for caregiver‑heavy neuromuscular trials, where the role of the family is central to study success.

Beyond execution: high-engagement, patient‑centric clinical trials

Stiris’ model goes beyond technical execution. We deliver a high-engagement approach that actively connects sites, patients, and caregivers throughout the study lifecycle, strengthening collaboration, building trust, and ensuring consistent support. By embedding this model into our operations, we reduce barriers to participation, ease burden on patients and families, and enable more inclusive and accessible research. The result is stronger retention, better representation, and higher-quality data in rare neuromuscular and neurological trials.

Our deep specialization in caregiver-intensive neuromuscular studies has established this area as a strategic growth engine. With proven experience across Phase II and III programs, including rescue studies, Stiris is the CRO biotech and pharmaceutical companies trust to guide programs from mid-phase through pivotal Phase III/IIIB execution, across North America and in global expansion.

Supporting your next neuromuscular and neurological clinical trial

Clinical trials in rare neuromuscular and neurological diseases require a different kind of CRO.  One that recognizes that the greatest risks to success are operational. Caregiver burden can limit participation and continuity, patient fatigue can affect retention and compliance, and site burden can slow enrollment and execution.

Stiris brings together expert clinical trial management, end-to-end development capabilities, and a deep understanding of these challenges. Our high-engagement model connects sites, patients, and caregivers to reduce burden, improve retention, and enable consistent execution across the study lifecycle.

Our experience in rescue studies demonstrates our ability to stabilize complex trials and recover execution where others have struggled. With 85% of our business coming from repeat and referral partners, we are a CRO trusted to deliver in the most demanding settings.

Stiris brings:
• A high-engagement model across sites, patients, and caregivers
• Proven success in rescue studies, stabilizing at-risk trials
• 85% repeat and referral business, reflecting strong sponsor trust
• Integrated, end-to-end clinical development capabilities

This is how we support the successful delivery of complex neuromuscular and neurology studies, by addressing the real barriers to execution while prioritizing patients and their caregivers.

To learn how we can help with your next clinical trial, contact us at info@stirisresearch.com.